World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
79403
World Ranking
14328
National Ranking
7244

Overview

Leora Horn is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology, pulmonary and respiratory medicine, cancer research, molecular biology, and epidemiology.

The scientist's work covers several main topics, including lung cancer treatments and mutations, lung cancer research studies, lung cancer diagnosis and treatment, COVID-19 and healthcare impacts, cancer genomics and diagnostics, neuroendocrine tumor research advances, and colorectal cancer treatments and studies.

Frequent venues for their publications include the Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, JTO Clinical and Research Reports, and Clinical Cancer Research.

They have published numerous papers, with some recent notable works as follows:

  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations, 2020, New England Journal of Medicine
  • Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133), 2021, Journal of Clinical Oncology
  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, 2020, The Lancet Oncology
  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer, 2020, Annals of Oncology
  • Immunotherapeutic approaches for small-cell lung cancer, 2020, Nature Reviews Clinical Oncology

Their frequent co-authors include Marina Chiara Garassino, Jennifer G. Whisenant, Heather A. Wakelee, Wade T. Iams, and Sally J. York.

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Leora Horn;Aaron S. Mansfield;Aleksandra Szczęsna;Libor Havel

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

    David S. Ettinger;Douglas E. Wood;Dara L. Aisner;Wallace Akerley

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

    David S. Ettinger;Douglas E. Wood;Charu Aggarwal;Dara L. Aisner

  • Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

    Scott Gettinger;Leora Horn;David Jackman;David Spigel

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

    Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

    David S. Ettinger;Wallace Akerley;Hossein Borghaei;Andrew C. Chang

Frequent Co-Authors

Heather A. Wakelee
Heather A. Wakelee Stanford University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Scott N. Gettinger
Scott N. Gettinger Yale University
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Scott J. Antonia
Scott J. Antonia Duke University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Tony Mok
Tony Mok Chinese University of Hong Kong
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA extends beyond the traditional MD path. Many healthcare professionals begin their journey with nursing degrees or specialized graduate programs. For those interested in pursuing advanced research or academic roles, a phd in nursing offers a blend of leadership opportunities and high-level expertise.

If you hold an RN and want to further your education, the cheapest rn to bsn program options make earning a bachelor’s degree accessible and affordable. Alternatively, non-nurses seeking quick entry into advanced nursing roles can consider online direct entry msn programs for non-nurses, which provide a streamlined path to becoming a nurse with a master’s degree.

For those starting out, associate degree nursing (adn programs) are often easier to get into and can lead to immediate employment opportunities. Whatever your background or career goals, these related online degrees offer flexible and cost-effective ways to enter or advance within the healthcare sector.

Best Scientists Citing Leora Horn

Trending Scientists